CLAIMS OF PATENTS DIRECTED TOWARD METHOD OF LOWERING RISK OF CHRONIC IMMUNE- MEDIATED DISORDER MET THRESHOLD OF ELIGIBILITY

摘要

The claims of patents that were directed toward a method of lowering the risk of chronic immune-mediated disorders, including a physical step of immunization in accordance with a lower-risk schedule, reasonably met the threshold of patent eligibility, despite operating on published information. Even if the claims appeared to raise cogent questions of substantive patentability, they had been directed toward a specific, tangible application. Classen Immuno-therapies, Inc. v. Biogen IDEC, 2011 WL 3835409 (Fed. Cir. 2011)